Fulcrum Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Fulcrum Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- FULC
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001680581
- EIN
- 47-4839948
Board of directors
-
Alan Ezekowitz · DirectorSince 2023
-
Alex Sapir · Director · See RemarksSince 2023
-
Colin Hill · DirectorSince 2024
-
James A. Geraghty · DirectorSince 2023
-
James J. Collins · DirectorSince 2023
-
Joshua Lehrer-Graiwer · DirectorSince 2026
-
Kate Haviland · DirectorSince 2023
-
Katina Dorton · DirectorSince 2023
-
Rachel K. King · DirectorSince 2024
-
Robert J. Gould · Director · Interim President & CEOSince 2023
-
Sonja Banks · DirectorSince 2023
Chief executives
Dates unknown
Director election results
Annual meeting of June 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
80.3%
-
97.3%
-
97.4%
Board connections
7 of this board's directors also sit on 12 other boards.
- via Kate Haviland
- via Kate Haviland
- via Rachel K. King
- via Joshua Lehrer-Graiwer
- via Rachel K. King
- via Alan Ezekowitz
- via James A. Geraghty
- via Katina Dorton
- via James J. Collins
- via Alan Ezekowitz
- via Katina Dorton
- via James A. Geraghty
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,485,743
- 6 purchases by 1 insider
- Sold, last 12 months
- $58,991,621
- 8 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 17, 2026 | Kevin Tang 10% owner | Open-market purchase | +50,945 | $3.52 | $179,326 |
| Jul 16, 2026 | Kevin Tang 10% owner | Open-market purchase | +116,671 | $3.56 | $415,349 |
| Jul 15, 2026 | Kevin Tang 10% owner | Open-market purchase | +107,377 | $3.56 | $382,262 |
| Jul 14, 2026 | Kevin Tang 10% owner | Open-market purchase | +53,651 | $3.56 | $190,998 |
| Jul 14, 2026 | Kevin Tang 10% owner | Open-market purchase | +75,952 | $3.58 | $271,908 |
| Jul 13, 2026 | Kevin Tang 10% owner | Open-market purchase | +12,966 | $3.54 | $45,900 |
| Jun 26, 2026 | Alan Ezekowitz Director | Open-market sale | −18,000 | $3.65 | $65,700 |
| Feb 2, 2026 | Robert J. Gould Director | Open-market sale | −15,000 | $10.72 | $160,800 |
| Jan 2, 2026 | Robert J. Gould Director | Open-market sale | −15,000 | $11.87 | $178,050 |
| Dec 15, 2025 | Oltmans Curtis Gale Officer (Chief Legal Officer) | Open-market sale | −3,452 | $12.92 | $44,600 |
| Dec 8, 2025 | RA Capital Healthcare Fund LP 10% owner | Open-market sale | −1,377,020 | $13.33 | $18,355,677 |
| Dec 8, 2025 | RA Capital Healthcare Fund LP 10% owner | Open-market sale | −2,706,397 | $14.28 | $38,647,349 |
| Dec 8, 2025 | RA Capital Healthcare Fund LP 10% owner | Open-market sale | −91,722 | $14.98 | $1,373,996 |
| Nov 19, 2025 | Robert J. Gould Director | Open-market sale | −15,000 | $11.03 | $165,450 |
| May 8, 2025 | Tourangeau Greg Officer (Principal Accounting Officer) | Open-market sale | −498 | $5.06 | $2,520 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.